Alexandria Hammond
Stock Analyst at B of A Securities
(2.79)
# 1,681
Out of 5,165 analysts
15
Total ratings
77.78%
Success rate
14.33%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alexandria Hammond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDGL Madrigal Pharmaceuticals | Maintains: Neutral | $570 → $529 | $440.83 | +20.00% | 3 | Feb 20, 2026 | |
| ABBV AbbVie | Downgrades: Peer Perform | n/a | $221.45 | - | 2 | Jan 8, 2026 | |
| MRK Merck & Co. | Upgrades: Outperform | $135 | $115.43 | +16.95% | 2 | Jan 8, 2026 | |
| REGN Regeneron Pharmaceuticals | Initiates: Outperform | $1,150 | $756.91 | +51.93% | 1 | Nov 15, 2024 | |
| PFE Pfizer | Initiates: Underperform | $25 | $26.61 | -6.05% | 1 | Nov 15, 2024 | |
| MRNA Moderna | Initiates: Underperform | $40 | $53.31 | -24.97% | 1 | Nov 15, 2024 | |
| LLY Eli Lilly and Company | Initiates: Outperform | $1,000 | $989.12 | +1.10% | 1 | Nov 15, 2024 | |
| JNJ Johnson & Johnson | Initiates: Outperform | $190 | $243.19 | -21.87% | 1 | Nov 15, 2024 | |
| GILD Gilead Sciences | Initiates: Outperform | $110 | $145.21 | -24.25% | 1 | Nov 15, 2024 | |
| BMY Bristol-Myers Squibb Company | Initiates: Peer Perform | n/a | $59.71 | - | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $183.26 | - | 1 | Nov 15, 2024 |
Madrigal Pharmaceuticals
Feb 20, 2026
Maintains: Neutral
Price Target: $570 → $529
Current: $440.83
Upside: +20.00%
AbbVie
Jan 8, 2026
Downgrades: Peer Perform
Price Target: n/a
Current: $221.45
Upside: -
Merck & Co.
Jan 8, 2026
Upgrades: Outperform
Price Target: $135
Current: $115.43
Upside: +16.95%
Regeneron Pharmaceuticals
Nov 15, 2024
Initiates: Outperform
Price Target: $1,150
Current: $756.91
Upside: +51.93%
Pfizer
Nov 15, 2024
Initiates: Underperform
Price Target: $25
Current: $26.61
Upside: -6.05%
Moderna
Nov 15, 2024
Initiates: Underperform
Price Target: $40
Current: $53.31
Upside: -24.97%
Eli Lilly and Company
Nov 15, 2024
Initiates: Outperform
Price Target: $1,000
Current: $989.12
Upside: +1.10%
Johnson & Johnson
Nov 15, 2024
Initiates: Outperform
Price Target: $190
Current: $243.19
Upside: -21.87%
Gilead Sciences
Nov 15, 2024
Initiates: Outperform
Price Target: $110
Current: $145.21
Upside: -24.25%
Bristol-Myers Squibb Company
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $59.71
Upside: -
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $183.26
Upside: -